Hadley and Notal Vision Partner to Empower Patients with Vision Loss Through Education and Leading Technology
Winnetka, Illinois--(Newsfile Corp. - June 24, 2025) - Hadley, a leading nonprofit empowering people with vision loss to adapt and thrive, and Notal Vision, a pioneer in AI-driven home diagnostic tools and digital healthcare for retinal diseases, today announced a strategic partnership to bridge the gap between early detection, treatment monitoring, and adaptive living for patients with age-related macular degeneration (AMD). The collaboration will connect users of Notal Vision's ForeseeHome and SCANLY Home OCT monitoring programs with Hadley's specialized programming, including Living with Macular Degeneration workshop series ( hadleyhelps.org/workshops/living-with-macular-degeneration ).
Notal Vision will connect patients experiencing vision loss to Hadley's free online practical and social/emotional content and programming. A co-produced podcast will feature experts discussing early detection of eye diseases and the role of at-home monitoring. Specifically, the partnership will highlight the combined benefits of Notal Vision's ForeseeHome and SCANLY Home OCT together with Hadley's free support.
Coordinated email campaigns and social media efforts will highlight the synergy between home monitoring and social/emotional programming and amplify resources for patients, family members, and caregivers.
'Hadley is thrilled to partner with Notal Vision to reach more individuals facing vision loss,' said Johnjoe Farragher, President & CEO of Hadley. 'Our Living with Macular Degeneration workshop, one of many social/emotional programs, provides Notal Vision patients with actionable tools to mitigate functional decline, complementing the critical role of ForeseeHome and SCANLY Home OCT in disease monitoring.'
'AMD management requires both technological and behavioral interventions,' noted Dr. Kester Nahen, CEO of Notal Vision. 'By referring our patients to Hadley's programs in our patient outreach, we empower individuals to proactively address vision changes - reducing anxiety and improving adherence to clinical follow-ups.'
About the Social / Emotional Programs & Technology Hadley's Living with Macular Degeneration : A workshop series covering assistive technology, home safety, and coping strategies, grounded in research on low-vision rehabilitation.
: A workshop series covering assistive technology, home safety, and coping strategies, grounded in research on low-vision rehabilitation. Notal Vision's ForeseeHome: An FDA-cleared medical device that uses AI to analyze at-home visual field data, helping clinicians detect wet AMD progression early with 81% of patients having functional vision of 20/40 or better at diagnosis (per Ho AC. et al., J. Clin. Med., 2021).
Notal Vision's SCANLY Home OCT: An FDA-cleared AI-powered medical device that allows physicians to track disease activity and treatment response in patients with wet AMD (per Holekamp NM et al., Retina 2024).
About Hadley
Hadley provides both practical help and social/emotional support to older adults adjusting to vision loss, empowering them to adapt and thrive. Founded in 1920, Hadley currently serves more than 150,000 individuals across the country and around the world. Visit hadleyhelps.org for more.
Contact Information: Burke Patten, Marketing Director, [email protected] ,
847-784-2869.
About Notal Vision
Notal Vision is a patient-centric digital healthcare provider extending retinal care from the clinic to the home. We empower physicians with innovative home-based technologies and home monitoring services that support patient management between office visits. Our solutions combine self-operated digital diagnostic devices, AI-enabled data analysis, and a physician-led monitoring center-all with the goal of helping preserve patients' vision. Learn more at www.notalvision.com .
Contact Information: Candice Morin, Communications Director,
[email protected] , 401-284-6378
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/256148
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
8 minutes ago
- New York Post
Are mRNA vaccines safe and effective? What to know as RFK Jr. halts funding
Vaccines using mRNA technology weren't immune to the latest round of federal research cuts. Health and Human Services Secretary Robert F. Kennedy Jr. said this week that he's pulling the plug on nearly $500 million in funding for the development of mRNA vaccines. The 22 projects are managed by the Biomedical Advanced Research and Development Authority (BARDA). 'The data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu,' Kennedy, a longtime vaccine critic, said in a statement. 'We're shifting that funding toward safer, broader vaccine platforms that remain effective even as viruses mutate.' 4 Health and Human Services Secretary Robert F. Kennedy Jr. said this week that he's pulling the plug on nearly $500 million in funding for the development of mRNA vaccines. AP Several studies have demonstrated that mRNA COVID-19 vaccines were over 90% effective at preventing severe illness and death. Vaccine researchers immediately took issue with the fiscal gutting, calling it a major setback for science. 'I don't think I've seen a more dangerous decision in public health in my 50 years in the business,' said Mike Osterholm, a University of Minnesota expert on infectious diseases and pandemic preparations. Here's a closer look at how mRNA vaccines work. What is mRNA? All living cells have ribonucleic acid, an essential biological molecule known as RNA. RNA's primary role in the body is to make proteins, which are needed for virtually every cellular process, from building and repairing tissues to defending the body from bacteria and viruses and transporting nutrients and oxygen. 4 The COVID-19 vaccine manufactured by Pfizer and Biontec is administered during a clinical trial. EPA/Biontech SE/Handout Proteins are synthesized using three main types of RNA — messenger RNA (mRNA), transfer RNA (tRNA) and ribosomal RNA (rRNA). MRNA's job is to carry information for protein making from DNA to the cell's ribosomes, where it's translated into proteins. How do mRNA vaccines work? MRNA can be created in a laboratory and injected into the body to instruct cells to make a protein associated with a specific virus. The body recognizes the protein as foreign and produces antibodies to combat it. When the actual virus or pathogen invades the body, the immune system is ready to neutralize it, preventing or reducing the severity of illness. Though mRNA was discovered in the early 1960s, the first mRNA vaccine wasn't approved for human use until 2020. 4 German firm BioNTech, Pfizer's partner on its Covid vaccine, is developing mRNA-based vaccines for cancers at a rapid pace. Photothek via Getty Images The US Food and Drug Administration (FDA) authorized Pfizer's COVID-19 vaccine for emergency use in December 2020 and later granted full approval. The vaccine uses mRNA to tell cells to make a harmless piece of the coronavirus's spike protein. Moderna's COVID-19 vaccine was also granted full approval by the FDA. MRNA vaccines are being explored for the treatment of cancer, food allergies and infectious diseases. Researchers say that mRNA vaccines can be developed faster than traditional vaccines because they do not require the time-consuming process of growing live virus cultures in a lab. 'The theoretical advantage of mRNA-based vaccines lies in their rapid adaptability,' Grant Hansman, senior research fellow at the Institute for Biomedicine and Glycomics at Griffith University in Australia, wrote this week in The Conversation. 'They will potentially allow annual updates to match circulating strains.' 4 University College London Hospital (UCLH) in London is testing novel cancer immunotherapy that aims to prevent skin cancer from recurring. The mRNA-based technology is for people who have already had high-risk melanomas removed. PA Images via Getty Images The Centers for Disease Control and Prevention notes that mRNA vaccines do not contain any live viruses or pathogens and do not alter a person's DNA. The mRNA molecule eventually breaks down in the body. The Cleveland Clinic reports that the risks of mRNA vaccines include pain or swelling at the injection site, fever, fatigue, headaches, muscle aches and allergic reactions. In his statement, Kennedy said that mRNA vaccines will be phased out in favor of whole killed virus vaccines, a traditional approach that uses entire pathogens that have been inactivated through heat, radiation or chemicals. Though it's a tried-and-true method of immunization, critics have raised concerns that these vaccines produce a weaker immune response than mRNA vaccines and pose manufacturing and logistical challenges. With Post wires
Yahoo
12 minutes ago
- Yahoo
Former FDA Director and Boston Scientific Leaders Join Keyron Ahead of Human Trials of First Device with Metabolic Surgery-Like Results Without Incisions
Former FDA Director David Feigal joins Keyron as Head of Regulatory Affairs Dr Joyce Peetermans (ex-Boston Scientific) joins as Acting CTO Christopher Rowland (ex-Boston Scientific) appointed Chairman ForePass aims to replicate metabolic surgery without incisions Preparing for First-In-Human trials after strong large-animal data Head-to-head data showing superiority over $28B/year drug to be published soon LONDON & BOSTON, August 06, 2025--(BUSINESS WIRE)--Keyron, a pioneer in medical devices for advanced metabolic disease, today announced the appointment of three world-class leaders to its board of directors—including the former Director of the FDA's Center for Devices and Radiological Health (CDRH) and senior medtech industry leaders with key roles in notable exits within the endoscopy medical device sector. These appointments strengthen Keyron's regulatory, clinical, and strategic leadership as the company prepares for its upcoming clinical trials, associated global regulatory submissions, and future strategic alliances, centered around its ForePass device. ForePass is designed to replicate the outcomes of metabolic surgery—without cutting, puncturing, or trauma—through a fully reversible, minimally invasive procedure. Board Appointments David Feigal MD (Head of Regulatory Affairs) – Former Director of the FDA's Center for Devices and Radiological Health (CDRH). Covered the highest role and authority in medical devices at the FDA. Brings decades of experience guiding breakthrough technologies through FDA approval and will now be the Company's lead for FDA engagement and IDE submission. Founder of leading U.S. regulatory consultancy, NDA Partners. Widely recognized as one of the most experienced regulatory experts in the U.S., he has held senior global roles at public companies Amgen and Elan and led or advised over 20 successful medical product approvals across therapeutic areas. Joyce Peetermans, Ph.D. (Acting CTO) – 35+ years of leadership roles in R&D, Clinical Research, and Innovation in Gastroenterological and Surgical Endoscopy, and other specialties. She spent 25 years at Boston Scientific, where she was on the Endoscopy Management Board as VP of Global Clinical Programs, and VP of Innovation and Research during the $615M acquisition of Apollo Endosurgery and several other key acquisitions by Boston Scientific Endoscopy. Christopher Rowland (Chairman) – A seasoned executive with over 35 years leading Class III endoscopic and metabolic device companies. He served as President at Given Imaging prior to its $860M PillCam exit to Covidien (Medtronic) and was CEO of Neotract before its $1.1B acquisition by Teleflex. He also spent 17 years in senior roles at Boston Scientific. Christopher will chair Keyron's board of directors and support its corporate development and fundraising strategy. This leadership expansion follows several successful large-animal studies of ForePass demonstrating excellent safety, tolerability, and strong efficacy on both weight and insulin production. Key results were published in Gut (Angelini G, Galvao Neto M, Boskoski I, et al., 2024), showing ForePass's ability to replicate surgery-like results without incisions. The company is now preparing to unveil best-in-class preclinical data showing clear superiority over Semaglutide—the $28B/year standard of care for obesity and diabetes in Ozempic and Wegovy—across all major endpoints. These data are expected to be published this summer. 92% of Semaglutide patients fail to achieve 15% total body weight loss (New England Journal of Medicine, 2021; 385(6):503–515), with 85% discontinuing GLP-1 therapy within just 24 months (Reuters, 10 July 2024). Yet patients with severe obesity (BMI ≥35)—especially those who also have type 2 diabetes—need around 30% weight loss. Since GLP-1s fall substantially short and most stop taking them, surgery remains the only viable option, regularly delivering over 30% weight loss despite its risks and complications. ForePass is a fully removable, endoscopically implantable device aiming to replicate the metabolic benefits of surgery without incisions. It targets patients with BMI ≥35 and diabetes or BMI ≥40—a large, high-risk population underserved by current treatments. Giorgio Castagneto Gissey, Founder & CEO of Keyron, said: "Christopher, David, and Joyce are absolute world-class leaders. Their decision to join Keyron reflects the urgency of the metabolic crisis—especially the unmet need in diabetes and higher BMI—and the unique power of what we've built. Their expertise will be transformative as we enter human trials and deliver the first truly effective, scalable alternative to surgery for millions." Keyron, a VC-backed startup, has developed a proprietary biometabolic implant and endoscopic delivery system, secured leading clinical sites in the U.S. and internationally, and completed long-term preclinical validation. Full efficacy results—including head-to-head data versus Semaglutide in a porcine model—will be published shortly. The company is now preparing for its First-In-Human study. About Keyron Keyron is the first biometabolic device platform company, pioneering a new class of implantable therapies that aim to replicate the effects of bariatric and metabolic surgery without incisions—and restore metabolic health at its root without driving insulin overproduction or dependency. Headquartered in London and Boston, Keyron's mission is to deliver a scalable alternative to surgery—and a better option for patients with severe obesity and diabetes. See for more information. View source version on Contacts Media Contact Keyron Press Officepress@ London, UK and Boston, MA Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
37 minutes ago
- Yahoo
OysterLink Poll: 1 in 4 Hospitality Workers Say Their Company Has No Job Openings in 2025
Los Angeles, California--(Newsfile Corp. - August 6, 2025) - A new poll from OysterLink finds that 26% of hospitality professionals say their company has no new jobs planned for 2025, raising questions about internal communication and hiring urgency within a sector still facing labor instability. Image 1To view an enhanced version of this graphic, please visit: The poll, which asked "Is your company currently hiring?", gathered more than a hundred responses from professionals in the restaurant and hospitality industry. Results showed: 26% – No new jobs planned 52% – I'm not currently with a company myself 13% – Hiring 1–10 new employees 9% – Hiring 10+ new employees The findings come as the latest data from the U.S. Bureau of Labor Statistics (BLS) shows a major decline in job openings in the sector. In June 2025, the number of openings in Accommodation and Food Services fell by 308,000, dropping from 1.06 million in May to 754,000—a sharp monthly decline that may reflect cooling demand or cautious hiring behavior. About OysterLink OysterLink is a leading job platform dedicated to the hospitality industry. We connect restaurants, hotels, and hospitality employers with skilled candidates across the U.S. With job listings, including server jobs in New York City or private chef jobs in Los Angeles, industry insights, and career resources, OysterLink helps professionals build rewarding careers in hospitality. Media ContactPR Representativeana@ To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
